Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NF1 Mutation”

28 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 28 results

Early research (Phase 1)Ended earlyNCT05831995
What this trial is testing

Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.

Who this might be right for
Advanced Solid TumorRAS MutationRAF Mutation+1 more
ABM Therapeutics Corporation 12
Large-scale testing (Phase 3)Active Not RecruitingNCT04576117
What this trial is testing

Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Who this might be right for
Recurrent Low Grade AstrocytomaRecurrent WHO Grade 2 GliomaRefractory Low Grade Astrocytoma+2 more
National Cancer Institute (NCI) 300
Testing effectiveness (Phase 2)Study completedNCT02101736
What this trial is testing

Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults

Who this might be right for
NF1NeurofibromatosisPlexiform Neurofibromas
University of Alabama at Birmingham 45
Not applicableLooking for participantsNCT04395495
What this trial is testing

RASopathy Biorepository

Who this might be right for
RAS MutationNeurofibromatosis 1Noonan Syndrome+11 more
Children's Hospital Medical Center, Cincinnati 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439318
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 50
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)Looking for participantsNCT05735717
What this trial is testing

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Who this might be right for
Hematologic MalignancyAcute LeukemiaRemission+21 more
Masonic Cancer Center, University of Minnesota 70
Testing effectiveness (Phase 2)Ended earlyNCT04534283
What this trial is testing

A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.

Who this might be right for
CancerCancer MetastaticBRAF V600E+4 more
Anita Turk 16
Early research (Phase 1)Temporarily pausedNCT03932253
What this trial is testing

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

Who this might be right for
Melanoma
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 79
Testing effectiveness (Phase 2)Study completedNCT02352844
What this trial is testing

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Who this might be right for
Solid MalignancySolid Tumor
Washington University School of Medicine 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT03872427
What this trial is testing

Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study

Who this might be right for
Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmNF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor+1 more
National Cancer Institute (NCI) 54
Not applicableUnknownNCT03757247
What this trial is testing

Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation

Who this might be right for
Neurofibromatosis Type 1
Medical University Innsbruck 670
Early research (Phase 1)Looking for participantsNCT03454035
What this trial is testing

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Who this might be right for
Tumor, SolidPancreatic CancerMelanoma
UNC Lineberger Comprehensive Cancer Center 45
Early research (Phase 1)Looking for participantsNCT06961565
What this trial is testing

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Who this might be right for
NF1 MutationNeurofibroma PlexiformNeurofibroma, Plexiform+2 more
Pasithea Therapeutics Corp. 56
Large-scale testing (Phase 3)Looking for participantsNCT04166409
What this trial is testing

The Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

Who this might be right for
Low Grade AstrocytomaLow Grade GliomaMetastatic Low Grade Astrocytoma+3 more
National Cancer Institute (NCI) 170
Testing effectiveness (Phase 2)Ended earlyNCT02315625
What this trial is testing

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more
National Cancer Institute (NCI) 16
Not applicableNot Yet RecruitingNCT06834438
What this trial is testing

Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002

Who this might be right for
NF2 Deficiency
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 9
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Early research (Phase 1)Ended earlyNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 29
Large-scale testing (Phase 3)Ended earlyNCT05130866
What this trial is testing

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Who this might be right for
Neurofibromatosis Type 2
Recursion Pharmaceuticals Inc. 25
Load More Results